시장보고서
상품코드
922031

교모세포종(GBM) 치료 시장 : 성장, 동향, 예측

Glioblastoma Multiforme Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

발행일: | 리서치사: Mordor Intelligence Pvt Ltd | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 교모세포종(GBM: Glioblastoma Multiforme) 치료 시장에 대해 조사하고, 시장 기회 및 동향, 성장 촉진요인 및 저해요인, 치료·최종사용자·지역별 시장 분석, 경쟁 상황, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서론

  • 조사결과
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 뇌질환 유병률 증가
    • 주요 기업의 강력한 연구개발 사업
    • 고령화 인구 증가
  • 시장 성장 저해요인
    • 상환 문제와 엄격한 규제 가이드라인
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 치료별
    • 화학요법
    • 방사선요법
    • 기타
  • 최종사용자별
    • 병원/진료소
    • 외래수술센터(ASC)
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Arbor Pharmaceuticals, LLC
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Merck & Co. Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

제7장 시장 기회 및 향후 동향

LSH 20.03.06

A brain tumor occurs when abnormal cells form as well as grow within a brain. Factors such as the increasing burden of brain disorders, strong R&D initiatives from key players and rising geriatric population are boosting the growth of the glioblastoma multiforme treatment market. As per the estimates of Globocan 2018, the number of new cases of brain cancer across the world was 296,851 in 2018. This leads to increased care providers shifting to the mainstream treatment associated with the glioblastoma treatment. Hence, the growing focus toward the development of better treatment options invites more cancer chemotherapy based companies to generate innovative drugs as well as explore different geographic regions to grow the sales of chemotherapy and radiation therapy products thus fueling the growth of glioblastoma multiforme treatment market.

However, reimbursement issues and stringent regulatory guidelines and high cost and side effects associated with therapies are expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Chemotherapy Segment is Expected to Dominate the Market

Based on treatment, the market is segmented into chemotherapy, radiation therapy, and others. The chemotherapy segment is expected to dominate the market. The key factor contributing to the growth of the segment is the rising number of brain and other nervous system cancers. Many companies are focusing on developing generic products for the treatment of neurological diseases like brain stroke; as well as glioblastoma in order to maintain their competitive advantage and penetrate new regional markets across the developed and emerging markets. In addition, the pipeline of glioblastoma multiforme is rich with the number of drugs that are expected to receive FDA approval steadily over the period. Also, an increase in funding for companies involved in the research related to glioblastoma is expected to boost the interest of venture partner companies, investors and new mergers as well as acquisition-related to this segment of the studied market.

North America leads the Glioblastoma Multiforme Treatment Market

North America leads the glioblastoma multiforme treatment market, owing to rise in funding initiatives and awareness among patients, followed by Europe. According to the American Society of Clinical Oncology (ASCO), in 2019, it was expected that an estimated 23,820 adults (13,410 men and 10,410 women) in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord. Brain tumors account for 85% to 90% of all primary CNS tumors. However, Asia Pacific is expected to grow at a faster rate due to the increasing awareness regarding advanced treatment options, and the presence of emerging economies in this region.

Competitive Landscape

The leading players in the global glioblastoma multiforme treatment market are - Arbor Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceutical and Teva Pharmaceutical Industries Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Brain Disorders
    • 4.2.2 Strong R&D Initiatives from Key Players
    • 4.2.3 Increasing Aging Population
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Issues and Stringent Regulatory Guidelines
    • 4.3.2 High Cost and Side Effects Associated with Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Chemotherapy
      • 5.1.1.1 Temozolomide
      • 5.1.1.2 Bevacizumab
      • 5.1.1.3 Carmustine
      • 5.1.1.4 Other Types of Chemotherapy
    • 5.1.2 Radiation Therapy
    • 5.1.3 Other Treatments
  • 5.2 By End User
    • 5.2.1 Hospitals/Clinics
    • 5.2.2 Ambulatory Surgical Centers
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arbor Pharmaceuticals, LLC
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Merck & Co. Inc.
    • 6.1.6 Sun Pharmaceutical Industries Ltd.
    • 6.1.7 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제